Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849612 · ClinicalTrials.gov registry record · NA
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
A NA study of Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03849612 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Eli Lilly and Company. The registered enrollment target is 10 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03849612, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.
Conditions Studied
Interventions
- DEVICE AID System
- DRUG Insulin Lispro
Study Locations (1)
California
- Diablo Clinical Research - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2019-03-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03849612
The ClinicalTrials.gov registry entry for NCT03849612 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (93% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which AID System is the first listed.
NCT03849612 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03849612 about?
NCT03849612 is a clinical study titled "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus". The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.
What is the current status of trial NCT03849612?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-02-21. Estimated completion is 2019-03-27.
What conditions does trial NCT03849612 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT03849612?
The interventions under investigation include: AID System (DEVICE), Insulin Lispro (DRUG).
Who is sponsoring clinical trial NCT03849612?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03849612 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.